XiangXue Life Sciences received US permission to start a Phase I trial of its high affinity specific T-cell receptor candidate, TCRT-ESO-A2. The molecule is China 's first TCR-T candidate to target solid tumors, aiming at tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients. XLifeSc is a subsidiary of Guangzhou XiangXue Pharma that focuses on TCR therapies for cancer. TCRT-ESO-A2 is being developed globally (ex-China) by Axis Therapeutics, a JV formed by XLifeSc and Athenex, a US-China biopharma. More details.... Stock Symbol: (SHZ: 300147) Share this with colleagues: // //